| 4.92 -0.05 (-1.01%) | 05-22 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.02 | 1-year : | 6.64 |
| Resists | First : | 5.16 | Second : | 5.68 |
| Pivot price | 5.11 |
|||
| Supports | First : | 4.31 | Second : | 3.59 |
| MAs | MA(5) : | 4.71 |
MA(20) : | 5.13 |
| MA(100) : | 5.62 |
MA(250) : | 4.76  |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 41.4 |
D(3) : | 27.7 |
| RSI | RSI(14): 45.7 |
|||
| 52-week | High : | 7.82 | Low : | 2.76 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ TARA ] has closed above bottom band by 35.3%. Bollinger Bands are 9.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.04 - 5.06 | 5.06 - 5.09 |
| Low: | 4.76 - 4.79 | 4.79 - 4.81 |
| Close: | 4.88 - 4.93 | 4.93 - 4.97 |
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.
Thu, 21 May 2026
Protara Therapeutics (TARA) Receives a Buy from Oppenheimer - The Globe and Mail
Thu, 21 May 2026
Piper Sandler Maintains Protara Therapeutics(TARA.US) With Buy Rating, Announces Target Price $24 - Moomoo
Thu, 21 May 2026
What's Driving Protara's Recent Surge - Kavout
Wed, 20 May 2026
Protara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA - Yahoo Finance
Tue, 19 May 2026
TARA: TARA-002 delivers strong, durable efficacy and safety for lymphatic malformations, targeting FDA approval - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 56 (M) |
| Shares Float | 49 (M) |
| Held by Insiders | 2.3 (%) |
| Held by Institutions | 81.9 (%) |
| Shares Short | 6,000 (K) |
| Shares Short P.Month | 5,550 (K) |
| EPS | -1.37 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.66 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -24.3 % |
| Return on Equity (ttm) | -37.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.25 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -63 (M) |
| Levered Free Cash Flow | -39 (M) |
| PE Ratio | -3.62 |
| PEG Ratio | 0 |
| Price to Book value | 1.34 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.39 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|